0.8616
Prelude Therapeutics Inc stock is traded at $0.8616, with a volume of 114.98K.
It is down -2.45% in the last 24 hours and up +19.67% over the past month.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$0.8832
Open:
$0.87
24h Volume:
114.98K
Relative Volume:
0.54
Market Cap:
$44.68M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-0.484
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
+6.37%
1M Performance:
+19.67%
6M Performance:
-44.41%
1Y Performance:
-77.74%
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PRLD
Prelude Therapeutics Inc
|
0.8616 | 44.68M | 0 | -131.52M | -107.56M | -1.78 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.47 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
599.76 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
600.51 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
256.16 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jul-29-22 | Initiated | Jefferies | Buy |
Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
Apr-26-21 | Initiated | H.C. Wainwright | Buy |
Mar-09-21 | Initiated | Barclays | Overweight |
Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
Oct-20-20 | Initiated | BofA Securities | Buy |
Oct-20-20 | Initiated | Goldman | Neutral |
Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
HC Wainwright Issues Positive Forecast for PRLD Earnings - Defense World
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know - MSN
Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Prelude Therapeutics reports preclinical profile of first-in-human SMARCA2 degrader - BioWorld MedTech
Prelude Therapeutics Founder Acquires 28% More Stock - Yahoo
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Prelude Therapeutics stock surges on insider buying By Investing.com - Investing.com India
Prelude Therapeutics stock surges on insider buying - Investing.com
Prelude Therapeutics chief chemistry officer acquires $69,250 in stock By Investing.com - Investing.com South Africa
Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock - Investing.com Australia
Prelude Therapeutics chief chemistry officer acquires $69,250 in stock - Investing.com
Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock By Investing.com - Investing.com South Africa
PRLD stock touches 52-week low at $0.66 amid sharp annual decline - Investing.com
Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ - openPR.com
Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock By Investing.com - Investing.com Australia
Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock - Investing.com India
Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MyChesCo
Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase - Investing.com Australia
Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase By Investing.com - Investing.com South Africa
Prelude Therapeutics’ SWOT analysis: biotech stock faces mixed outlook amid clinical trials - Investing.com Australia
NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial - MyChesCo
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares By Investing.com - Investing.com South Africa
Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares - Investing.com
Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements - MyChesCo
Barclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD) - The Globe and Mail
Rhumbline Advisers Purchases 154,826 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Rhumbline Advisers Increases Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - The AM Reporter
Prelude Therapeutics Reports 2024 Financial Results - TipRanks
Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77) - TipRanks
Prelude Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Prelude Therapeutics Inc SEC 10-K Report - TradingView
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewswire
PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat - MyChesCo
Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo
Prelude Therapeutics to Present at Barclays Global Healthcare Conference - MSN
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MyChesCo
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewswire
How Will Prelude's Cancer Pipeline Updates Impact Investors at Upcoming Barclays Conference? - StockTitan
Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MyChesCo
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully - Yahoo Finance
Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MSN
PRLD stock touches 52-week low at $0.79 amid market challenges - Investing.com
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):